OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TTD57

Tam Duc Cardiology Hospital JSC

Healthcare Facilities & ServicesVerified

Tam Duc Cardiology Hospital JSC maintains a strong liquidity position, with a current ratio of 3.35, indicating that the company has more than three times the current assets to cover its current liabilities. The company holds VND 30 billion in cash and equivalents, and its operating cash flow of VND 112.47 billion supports its liquidity needs without reliance on long-term debt, as the company has no long-term debt obligations. The company's profitability is robust, with a return on equity (ROE) of 26.62% and a return on assets (ROA) of 21.62%, both significantly above the typical thresholds for healthcare facilities. These metrics suggest efficient use of equity and assets to generate returns, aligning with the industry's preference for high ROE and ROA as indicators of operational efficiency. Geographically, Tam Duc Cardiology Hospital JSC is concentrated in Vietnam, with all operations and revenue derived from this market. The company's revenue is not disclosed by segment, but its business model is centered on cardiology services, which may expose it to local healthcare demand and regulatory changes. The lack of diversification could pose a risk if the domestic healthcare market experiences volatility. The company's growth trajectory is positive, with a strong net income of VND 95.74 billion and a gross profit of VND 183.78 billion. While no specific growth rates are provided, the company's operating income of VND 106.38 billion and free cash flow of VND 38.52 billion suggest a capacity for reinvestment and expansion. The capital expenditure of VND -23.92 billion indicates ongoing investment in infrastructure or equipment, which could support future growth. Risk factors for Tam Duc Cardiology Hospital JSC are minimal in the short term, with no immediate liquidity or dilution flags detected. The company's low debt-to-equity ratio of 0.0 and strong cash reserves reduce financial risk. However, the absence of long-term debt could also limit the company's ability to leverage capital for growth. The risk assessment indicates low dilution potential, with no recent or pending share issuance events reported. Recent events and filings for Tam Duc Cardiology Hospital JSC do not indicate any material changes in its financial or operational status. The company's financial snapshot and valuation metrics remain stable, with no significant deviations from historical performance. The absence of recent regulatory or legal issues suggests a stable operating environment, although the company's exposure to the Vietnamese healthcare sector remains a key factor to monitor.

30-day price · TTD-25871.87 (-20.2%)
Low$102500.01High$159279.88Close$102500.01As of25 May, 00:00 UTC
Profile
CompanyTam Duc Cardiology Hospital JSC
TickerTTD.HNO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Tam Duc Cardiology Hospital JSC operates a cardiology hospital in Vietnam, providing diagnostic, surgical, treatment, and recovery services for inpatients and outpatients, generating revenue primarily through healthcare service fees.

Classification. Tam Duc Cardiology Hospital JSC is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

Tam Duc Cardiology Hospital JSC maintains a strong liquidity position, with a current ratio of 3.35, indicating that the company has more than three times the current assets to cover its current liabilities. The company holds VND 30 billion in cash and equivalents, and its operating cash flow of VND 112.47 billion supports its liquidity needs without reliance on long-term debt, as the company has no long-term debt obligations. The company's profitability is robust, with a return on equity (ROE) of 26.62% and a return on assets (ROA) of 21.62%, both significantly above the typical thresholds for healthcare facilities. These metrics suggest efficient use of equity and assets to generate returns, aligning with the industry's preference for high ROE and ROA as indicators of operational efficiency. Geographically, Tam Duc Cardiology Hospital JSC is concentrated in Vietnam, with all operations and revenue derived from this market. The company's revenue is not disclosed by segment, but its business model is centered on cardiology services, which may expose it to local healthcare demand and regulatory changes. The lack of diversification could pose a risk if the domestic healthcare market experiences volatility. The company's growth trajectory is positive, with a strong net income of VND 95.74 billion and a gross profit of VND 183.78 billion. While no specific growth rates are provided, the company's operating income of VND 106.38 billion and free cash flow of VND 38.52 billion suggest a capacity for reinvestment and expansion. The capital expenditure of VND -23.92 billion indicates ongoing investment in infrastructure or equipment, which could support future growth. Risk factors for Tam Duc Cardiology Hospital JSC are minimal in the short term, with no immediate liquidity or dilution flags detected. The company's low debt-to-equity ratio of 0.0 and strong cash reserves reduce financial risk. However, the absence of long-term debt could also limit the company's ability to leverage capital for growth. The risk assessment indicates low dilution potential, with no recent or pending share issuance events reported. Recent events and filings for Tam Duc Cardiology Hospital JSC do not indicate any material changes in its financial or operational status. The company's financial snapshot and valuation metrics remain stable, with no significant deviations from historical performance. The absence of recent regulatory or legal issues suggests a stable operating environment, although the company's exposure to the Vietnamese healthcare sector remains a key factor to monitor.
Key takeaways
  • Tam Duc Cardiology Hospital JSC has a strong liquidity position with a current ratio of 3.35 and no long-term debt.
  • The company's profitability is robust, with a return on equity of 26.62% and a return on assets of 21.62%.
  • The company is geographically concentrated in Vietnam, with all operations and revenue derived from this market.
  • The company's growth trajectory is supported by strong net income and free cash flow, with ongoing capital expenditures.
  • Risk factors are minimal in the short term, with no immediate liquidity or dilution flags detected.
  • The company's recent financial and operational status remains stable, with no significant deviations from historical performance.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyVND
Revenue$835.78B
Gross profit$183.78B
Operating income$106.38B
Net income$95.74B
R&D
SG&A
D&A
SBC
Operating cash flow$112.47B
CapEx-$23.92B
Free cash flow$38.52B
Total assets$442.78B
Total liabilities$83.11B
Total equity$359.67B
Cash & equivalents$30.00B
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$359.67B
Net cash$30.00B
Current ratio3.4
Debt/Equity0.0
ROA21.6%
ROE26.6%
Cash conversion1.2%
CapEx/Revenue-2.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricTTDActivity
Op margin12.7%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin11.5%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin22.0%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-2.9%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity0.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 05:19 UTC#85c60a1d
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 05:21 UTCJob: b40283ff